Last $0.85 USD
Change Today +0.09 / 11.84%
Volume 2.0M
ACUR On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

acura pharmaceuticals inc (ACUR) Snapshot

Open
$0.85
Previous Close
$0.76
Day High
$1.15
Day Low
$0.81
52 Week High
03/3/14 - $2.10
52 Week Low
12/2/14 - $0.41
Market Cap
41.5M
Average Volume 10 Days
314.5K
EPS TTM
$-0.28
Shares Outstanding
48.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACURA PHARMACEUTICALS INC (ACUR)

acura pharmaceuticals inc (ACUR) Related Businessweek News

No Related Businessweek News Found

acura pharmaceuticals inc (ACUR) Details

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company’s products include Oxecta tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed, a pseudoephedrine HCl tablet that is used as a nasal decongestant in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has a license, development, and commercialization agreement with King Pharmaceuticals Research and Development, Inc. to manufacture and commercialize Oxecta products in the United States, Canada, and Mexico. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.

15 Employees
Last Reported Date: 03/3/14
Founded in 1935

acura pharmaceuticals inc (ACUR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $383.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $219.0K
Vice President of Technical Affairs
Total Annual Compensation: $282.0K
Vice President, Treasurer and Corporate Contr...
Total Annual Compensation: $170.0K
Vice President of Marketing
Total Annual Compensation: $155.0K
Compensation as of Fiscal Year 2013.

acura pharmaceuticals inc (ACUR) Key Developments

Acura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations

Acura Pharmaceuticals, Inc. announced the initiation of treatment in a pilot clinical study of two experimental formulations of NEXAFED (pseudoephedrine HCl) extended-release tablets employing Acura's 2nd generation methamphetamine resistant technology, IMPEDE 2.0. The study in fasted, healthy subjects will measure the systemic absorption of the active ingredient, pseudoephedrine, from two experimental NEXAFED extended-release formulations compared to an FDA-approved 12-hour extended-release reference product. The objective of the study is to characterize the bioavailability profile of the NEXAFED formulations for possible adjustment before pivotal human pharmacokinetic testing is undertaken. The experimental NEXAFED extended-release formulations include Acura's enhanced IMPEDE 2.0 technology that delivers superior meth-resistance in the direct conversion, or one-pot, methamphetamine conversion process compared to IMPEDE 1.0 and other meth-resistant technologies in the market. IMPEDE 2.0 in the extended-release formulation has demonstrated, in direct conversion tests performed by an independent, international pharmaceutical services company, the ability to reduce meth-yields, on average, by 75% compared to Sudafed® Tablets.

Acura Pharmaceuticals, Inc. Expands Meth-Resistant Decongestant Line with NEXAFED Sinus Pressure + Pain

Acura Pharmaceuticals, Inc. announced the launch of their second pseudoephedrine (PSE) product, NEXAFED Sinus Pressure + Pain. NEXAFED Sinus Pressure + Pain [pseudoephedrine HCI 30mg + acetaminophen 325mg] is a meth-resistant immediate-release tablet that effectively relieves congestion due to colds and allergies, as well as pain and/or fever associated with colds and sinus headaches. NEXAFED Sinus Pressure + Pain will continue to utilize NEXAFED's unique, patented IMPEDE technology that disrupts the conversion of PSE into the dangerous drug methamphetamine (meth), and will be the first meth-resistant PSE combination sinus medicine available. Pseudoephedrine is the preferred decongestant used in most cold medications, but is commonly used in the illegal manufacturing of meth. NEXAFED's IMPEDE technology significantly disrupts the conversion of PSE to meth, making it virtually useless for meth production.

Acura Pharmaceuticals, Inc. - Special Call

To discuss the Agreement with Egalet on font-weight

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACUR:US $0.85 USD +0.09

ACUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $1.05 USD -0.02
Johnson & Johnson $102.51 USD -0.29
Perrigo Co PLC $154.47 USD -0.78
View Industry Companies
 

Industry Analysis

ACUR

Industry Average

Valuation ACUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 161.8x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 67.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACURA PHARMACEUTICALS INC, please visit www.acurapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.